#SJIC CEO Barnaby Perks was delighted to present Healx with the Business Weekly Life Science AI Award at the recent ceremony. Congratulations to all the winners, everyone nominated, the organisers and fellow sponsors. It was a great evening! #Cambridge #Awards

Exciting Progress in Rare Disease Treatment at Healx! Proud to share that our lead program, HLX-1502, has received FastTrack designation from the FDA, bringing us one step closer to delivering a breakthrough treatment for neurofibromatosis type 1 (NF1). This designation

Growth is a journey fuelled by curiosity, collaboration, and mutual respect for one another. Our team is dedicated to learning, sharing knowledge, and amplifying every voice to drive meaningful impact for the #raredisease community. By embracing diverse perspectives and fostering

Our Senior Director, Drug Discovery and Head of Operations, People & Tech will be participating in the OBN_UK BioTuesday session next week in London. They will contribute to a conversation about the funding landscape and regulatory challenges within the #raredisease space and

Important collaboration update: we just announced that we will be analyzing data from a proprietary Sanofi compound using Healnet, our #AI-driven #drugdiscovery platform, in order to identify new disease indications for this asset. Read More: healx.ai/healx-announce…

We are proud to partner with the Children's Tumor Fdn Foundation (CTF) since 2020 to combine our cutting-edge #AI platform and drug discovery expertise with CTF’s preclinical and clinical research and patient knowledge in identifying novel treatments for #rarediseases including

We're extending our sincerest congratulations to Healx Co-founder David Brown, Ph.D., for being awarded the 2024 OBN_UK Awards Special Recognition Award. Over the span of 50 years, and in addition to his leadership at Healx, he has worked with leading pharmaceutical companies

We are pleased to announce the appointment of Jonathan Milner, Ph.D., as the new non-executive chairman of the board, effective immediately. Dr. Milner is a distinguished entrepreneur and an influential figure in the UK life sciences and #biotech industry with a strong track

Our co-founder and CEO Tim Guilliams is looking forward to participating in a panel discussion on how #AI is reshaping healthcare at @Balderton’s “From code to cure: AI's reshaping of drug discovery” event in London. Tim will highlight how Healx is leveraging generative AI to

Another quarterly team days meeting in the books! We enjoyed coming together in Cambridge one final time before the end of the year to reflect on the progress made in 2024 and the strides we have made in leveraging the power of generative AI to bring new treatments to patients.

Excited for #JPM25 next week in San Francisco! Our CEO, Tim Guilliams, will be there—say hello if you see him! Let’s connect to share insights and collaborate on transforming lives for #raredisease patients through generative #AI. #AIForGood #HealthcareInnovation

Our CEO @TimGuillams sat down with the Global Genes RARECast podcast team to discuss the unique ways Healx is harnessing #AI to develop treatments for #rarediseases, starting with neurofibromatosis type 1 (#NF1). Listen now for more on Healx’s origins, our progress to date, and

In honor of International Day of Women and Girls in Science, we’re celebrating the incredible women at Healx who are helping to pave the way in AI-driven drug discovery for #rarediseases. We believe in fostering a more inclusive future where women and girls are empowered to shape

🚀 Big milestone! The first patient has been dosed in INSPIRE-NF1, our Phase 2 study of HLX-1502 for #NF1, a rare genetic disorder affecting ~1 in 2,500 people. This is a huge step forward in our mission to use #AI & tech to drive breakthroughs for #raredisease patients. Hear

From shared vision to changing lives. In 2013, our co-founders Dr. David Brown & Tim Guilliams met for the first time — a conversation that sparked the creation of Healx and a new approach to discovering and developing treatments for rare diseases. Now, we’ve just dosed the first

Big news! 🚀 Healx welcomes Dr. Chris Moertel as our Global Head of Clinical Development. His expertise in #Neurofibromatosis and rare disease clinical research will accelerate our mission. Welcome, Chris! 🎉 #RareDisease #DrugDiscovery #ClinicalDevelopment

We’re partnering with SCI Ventures to use AI to uncover treatments for paralysis. Together, we aim to accelerate therapies for spinal cord injury and beyond. 🚀 Learn more: healx.ai/healx-and-sci-…